A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.

Takashi KasaiKiyoshi MoriKazuma KishiTakayuki KaburagiYukio HosomiHisao ImaiYutaka YamadaMakiko YomotaSyuhei MoriguchiMasahiro SeikeKoichi MinatoAkihiko Gemmanull null

Published in: International journal of clinical oncology (2020)

The recommended doses for this combination therapy are carboplatin AUC 5 and S-1 80 mg/m2/day every 3 weeks, and this combination is effective with tolerable toxicities for advanced NSCLC patients ≥ 75 years old.

Keyphrases

advanced non small cell lung cancer
combination therapy
ejection fraction
newly diagnosed
small cell lung cancer
prognostic factors
clinical trial
squamous cell carcinoma
patient reported outcomes
patient reported
gestational age